Skip to main content
. 2024 May 22;16(5):e60851. doi: 10.7759/cureus.60851

Table 7. Adverse reactions in patients treated with amivantamab.

Risk level Adverse reaction
High risk ≥15% General disorders and administrative site conditions (17%); Injuries, poisonings, and complications (17%).
Medium risk 5-15 Gastrointestinal disorders (5%); Infections and infestations (7%); Benign neoplasms (6%)
Low risk ≤5% Blood and lymphatic system disorders (1%); Cardiac disorders (2%); Eye disorders (1%); Immune system disorders (1%); Metabolism and nutrition disorders (1%)